Evidence map›Paper›PMID 35287672›Full record

Observational studyJournal of translational medicine2022

Superior physical and mental health of healthy volunteers before and five years after mobilized stem cell donation.

J Heyn, S Bräuninger, M Dimova-Dobreva, N Mathieson, N Koptelova, A Kolpakova, C Seidl, P Reinhardt, C Tsamadou, H Schrezenmeier and 3 more

Registry-linked trialAbstract readObservational Study
In one paragraph

Observational study in Journal of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01766934 (Non-interventional, Prospective, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Healthy Unrelated Stem Cell Donors Undergoing Peripheral Blood Progenitor Cell Mobilization), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01766934 completednot on this map

Non-interventional, Prospective, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Healthy Unrelated Stem Cell Donors Undergoing Peripheral Blood Progenitor Cell Mobilization

TypeobservationalSponsorSandozRan2011 to 2024Enrolled245ConditionsHematopoietic Stem Cell Mobilization
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

J HeynHexal AG (a Sandoz Company), Holzkirchen, Germany.
S BräuningerGerman Red Cross Blood Service Baden-Württemberg-Hessen, Institute Frankfurt, Frankfurt, Germany.
M Dimova-DobrevaHexal AG (a Sandoz Company), Holzkirchen, Germany.
N MathiesonHexal AG (a Sandoz Company), Holzkirchen, Germany.
N KoptelovaHexal AG (a Sandoz Company), Holzkirchen, Germany.
A KolpakovaHexal AG (a Sandoz Company), Holzkirchen, Germany.
C SeidlGerman Red Cross Blood Service Baden-Württemberg-Hessen, Institute Frankfurt, Frankfurt, Germany.
P ReinhardtInstitut für Klinische Transfusionsmedizin und Immungenetik Ulm (IKT), Ulm, Germany.
C TsamadouInstitut für Klinische Transfusionsmedizin und Immungenetik Ulm (IKT), Ulm, Germany.
H SchrezenmeierInstitut für Klinische Transfusionsmedizin und Immungenetik Ulm (IKT), Ulm, Germany.
R NakovHexal AG (a Sandoz Company), Holzkirchen, Germany.
E SeifriedGerman Red Cross Blood Service Baden-Württemberg-Hessen, Institute Frankfurt, Frankfurt, Germany.
H BonigGerman Red Cross Blood Service Baden-Württemberg-Hessen, Institute Frankfurt, Frankfurt, Germany. h.boenig@blutspende.de.ORCID 0000-0003-0088-2675

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSafety, tolerability and efficacy of granulocyte colony-stimulating factor (G-CSF) for mobilization of hematopoietic stem and progenitor cells (HSPCs) from healthy donors have been conclusively demonstrated. This explicitly includes, albeit for smaller cohorts and shorter observation periods, biosimilar G-CSFs. HSPC donation is non-remunerated, its sole reward being "warm glow", hence harm to donors must be avoided with maximal certitude. To ascertain, therefore, long-term physical and mental health effects of HSPC donation, a cohort of G-CSF mobilized donors was followed longitudinally.

methodsWe enrolled 245 healthy volunteers in this bi-centric long-term surveillance study. 244 healthy volunteers began mobilization with twice-daily Sandoz biosimilar filgrastim and 242 underwent apheresis after G-CSF mobilization. Physical and mental health were followed up over a period of 5-years using the validated SF-12 health questionnaire.

resultsBaseline physical and mental health of HSPC donors was markedly better than in a healthy reference population matched for ethnicity, sex and age. Physical, but not mental health was sharply diminished at the time of apheresis, likely due to side effects of biosimilar G-CSF, however had returned to pre-apheresis values by the next follow-up appointment after 6 months. Physical and mental health slightly deteriorated over time with kinetics reflecting the known effects of aging. Hence, superior physical and mental health compared to the general healthy non-donor population was maintained over time.

conclusionsHSPC donors are of better overall physical and mental health than the average healthy non-donor. Superior well-being is maintained over time, supporting the favorable risk-benefit assessment of volunteer HSPC donation. Trial registration National Clinical Trial NCT01766934.

Indexed as

Hematopoietic Stem Cell MobilizationMental HealthGranulocyte Colony-Stimulating FactorHealthy VolunteersHematopoietic Stem CellsHumansGranulocyte Colony-Stimulating FactorFilgrastimHealthy stem cell donorsPhysical and mental healthSF-12

Identifiers

PMID35287672
PMCPMC8919626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.